IP Strategies for Health Sciences Startups

IP Strategies for Health Sciences Startups

Speaking Engagement
Biotech and medical device companies are heavily dependent on intellectual property rights, particularly those developing diagnostic, therapeutic or invasive products. The complexity of the technology and rapidly evolving legal landscape make the availability, validity and enforceability of biotech patents highly uncertain. This session, led by Michael Twomey, a patent attorney and partner at WilmerHale, will explore some of the basic IP questions facing health sciences startups.

Read More About the Event

You May Be Interested In

International Trade Post-Election Update: What to Expect in the New Administration

January 9, 2025
Webinar

Banking Law Committee Meeting 2025

January 10, 2024
Speaking Engagement

The Federal Trade Commission: Priorities for 2025

January 14, 2025
Webinar
View all Events

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel